ISIS 678354-CS9: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia

Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis

Percent change in fasting TG from Baseline at Week 25 compared to placebo.

Percent change in fasting TG from Baseline at Week 53 compared to placebo, Proportion of patients who achieve fasting TG < 150 mg/dL (1. 69 mmol/L) at Week 25 and proportion of patients who achieve fasting TG < 150 mg/dL at Week 53 compared to placebo, Percent change in fasting apoC-III, VLDL-C, remnant cholesterol, non-HDL-C, HDL-C, apoB, and LDL-C from Baseline at Week 25 and at Week 53 compared to placebo, Safety and tolerability assessments include: adverse events (AEs), vital signs and weight, physical examinations, clinical laboratory tests, electrocardiogram (ECG), and use of concomitant medications. Safety and tolerability results in patients receiving olezarsen will be compared with those receiving placebo.

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Bulgaria, Czechia, Denmark, Finland, France, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Slovakia, Spain